MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Health Care · Biotechnology · NASDAQ
Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
What MADRIGAL PHARMACEUTICALS, INC. does
Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of liver diseases. Its primary product is Rezdiffra (resmetirom), an oral, once-daily, liver-directed thyroid hormone receptor (THR)-β agonist approved for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Themes: liver disease, MASH / NASH, metabolic disorders
Fundamentals
- Price$538.88 as of 2026-08-26 close
- Market cap$12.5B as of 2026-08-26
- 1-year return+26.8% 2025-08-26 close $424.86 → 2026-08-26 close $538.88
- P/En/a negative earnings
- Net margin-25.3% as of 2026-08-26
- Gross margin+91.5% as of 2026-08-26
- ROE-56.6% as of 2026-08-26
- Debt / equity0.65 as of 2026-08-26
- Revenue growth (YoY)+149.0% as of 2026-08-26
- Beta0.65 as of 2026-08-26
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How MDGL compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-26
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-26
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MDGL is not currently in any published Top 10 list. Its scores are below.
Long-term score
41.3 #1267 of 1,608 scored · #148 of 198 in Health Care
Growth 100th (revenue growth year over year 149%) and long-term trend 52nd (a "golden cross" — its 50-day average is above its 200-day); weakest is profitability (5th, return on equity -56.6%, operating margin -25.3%).
Short-term score
46.3 #887 of 1,696 scored · #149 of 239 in Health Care
Catalysts 55th: open-market insider buys in 90 days 15, the analyst consensus rating is unchanged since the prior reading; trend 53rd: a "golden cross" — its 50-day average is above its 200-day; weakest is volume and participation 28th: trading volume is about normal versus its 30-day average.
Scores as of 25 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How MADRIGAL PHARMACEUTICALS, INC. looks technically
MADRIGAL PHARMACEUTICALS, INC. (MDGL) is trading 5.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 250 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 19 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 5.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +5.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $524.99 | $524.99 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $513.43 | $513.43 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 494.9. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 250 trading days ago — a "golden cross", a bullish long-term signal | 250 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 5.0% above | +5.0% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 11.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 55.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($494.90 to $550.33) — its "stochastic" reading is 79 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 79.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $615.00 | $615.00 |
|---|---|---|
| From the 52-week high | it is 12.4% below its 52-week high (its highest price of the past year) | -12.4% |
| Above the 52-week low | it is 43.9% above its 52-week low (its lowest price of the past year) | +43.9% |
| Below the 52-week high | it is 12.4% below its highest point of the past year | 12.4% |
| Since a 20-day breakout | it made a new 20-day low about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $615.00 (set on 2025-12-24) | $615.00 |
| Given back of the 52-week move | over the past year its closes ranged ($379.55 to $602.83), and it has given back roughly a quarter of its rise from last year’s low — 29% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $457.70 to $464.84. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 28.6% |
| From the all-time high | it is 12.4% below its all-time high | -12.4% |
| Nearest price level | it is trading 0.6% above a support level at $535.54 — a price it turned at twice since 2025-12-18, most recently on 2026-05-27. Since 2024-08-26 it has 12 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.6% |
| All-time low | its lowest closing price on record is $5.17 (set on 2016-02-08) | $5.17 |
| Above the all-time low | it is 10318.3% above its all-time low | +10,318% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 36th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $22.47 between its high and its low — about 4.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $22.47 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $478.20 and $549.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $478.20 – $513.72 – $549.25 |
| Typical daily range (% of price) | its price moves about 4.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.2% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges above its 200-day average price (5.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.01× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-26 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 16 sessions ago and has not traded back through the level it left behind at 482 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 7.6% gap down opened on 2026-07-30 has been "filled" today — price traded back through the level the gap left behind, and it took 19 sessions to close | today |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +5.26% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.7 percentage points (the stock lost 1.0% while the market gained 3.7%) | -4.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 0.7 percentage points (the stock gained 2.8% while the market gained 2.1%) | +0.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 9.7 percentage points (the stock gained 20.9% while the market gained 11.1%) | +9.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 8.1 percentage points (the stock gained 26.8% while the market gained 18.7%) | +8.1% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.6% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.3% of the share price. | +1.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $502.25 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +7.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $507.04 — a volume-weighted average of daily closes over 20 sessions, not a true tick-by-tick VWAP. | +6.3% |
Price levels it has turned at before
MDGL last closed at $538.88 on 2026-08-26. Since 2024-08-26 it has turned at 12 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $535.54 | Support | 0.6% below the last close | turned there twice · 2025-12-18 to 2026-05-27 |
| $545.87 | Resistance | 1.3% above the last close | turned there twice · 2026-05-14 to 2026-08-12 |
| $566.70 | Resistance | 5.2% above the last close | turned there four times · 2026-03-26 to 2026-07-27 |
| $506.97 | Support | 5.9% below the last close | turned there twice · 2026-01-28 to 2026-04-10 |
| $496.98 | Support | 7.8% below the last close | turned there five times · 2026-02-10 to 2026-08-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $494.90.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 4 trading days, since 2026-08-21.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · beating the market · Printed a bullish engulfing pair | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.29 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$678.06 range $543.00 – $962.00; median $651.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MDGL
- Consensus EPS estimate-$1.09 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a single approved product (Rezdiffra) for commercial success.","Uncertainty regarding long-term market acceptance, reimbursement, and pricing by third-party payors.","Potential failure to maintain regulatory approvals or expand indications in a competitive landscape."]
What changed in the latest 10-Q
AI-assisted comparison of MDGL's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) adds section header 'Overview' before company description
- Newer filing adds: 'Following receipt of conditional marketing authorization ("CMA") from the European Commission ("EC"), we launched Rezdiffra in Germany in September 2025.'
- Newer filing adds: 'In addition, we are advancing a focused pipeline to lead the evolution of MASH treatment for patients for decades to come. Through our business development efforts, we have acquired rights to MGL-2086, an oral glucagon-like peptide-1 ("GLP-1") receptor agonist, ervogastat, an oral diacylglycerol O-acyltransferase 2 ("DGAT-2") inhibitor, six small interfering RNA ("siRNA") programs and additional preclinical MASH candidates.'
- Newer filing adds section header 'Approval of Rezdiffra' and reorganizes approval discussion
- Newer filing adds section header 'Market Opportunity for Rezdiffra in MASH'
- Newer filing adds updated patient numbers: 'Through 2025, we estimate that the number of patients under specialist care in the U.S. has grown nearly 50% to approximately 460,000 patients with moderate to advanced fibrosis'
- Newer filing adds: 'During our first six quarters of launch in the United States, we focused our efforts on hepatologists and gastroenterologists. Beginning in the fourth quarter of 2025, we expanded our field team to further target select endocrinologists that provide care to MASH patients.'
- Newer filing adds: 'Beyond Germany, we expect to launch Rezdiffra on a country-by-country basis in Europe dependent on multiple factors, including the completion of reimbursement procedures and regulatory approval where required.'
- Newer filing adds: 'In addition, we may enter into distribution agreements with third parties to distribute Rezdiffra in smaller European countries and in other jurisdictions globally.'
- Newer filing adds 'Key Developments' section with: 'In January 2026, we announced the expansion of our pipeline with an exclusive global license with Pfizer Inc. (the "Pfizer License Agreement") for ervogastat, an oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inflammation. In the fourth quarter of 2026, we plan to initiate a drug-to-drug interaction study with resmetirom and consult with the FDA on the design of a P'
- Removed:
- Older filing (2025-11-04) reference to 'year ended December 31, 2024' removed; newer filing references 'year ended December 31, 2025'
- Older filing statement 'In August 2025, the European Commission ("EC") approved Rezdiffra and we launched Rezdiffra in Germany in September 2025' removed
- Older filing statement 'Rezdiffra is the first and only medication approved by both the FDA and EC' changed to 'Rezdiffra was the first medication approved by both the FDA and EC'
- Older filing section header 'MASH Disease State Overview' removed; content consolidated under 'Market Opportunity' header
- Older filing removed statement: 'Patients with compensated MASH cirrhosis (consistent with F4c fibrosis) have a 42-times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop.'
- Older filing section header 'Our Patient Focus' removed
- Older filing detailed patient population data removed: 'approximately 1.5 million patients have been diagnosed with MASH in the United States, of which approximately 525,000 have MASH with moderate to advanced fibrosis' and reference to 'approximately 14,000 specialist prescribers'
- Older filing removed: 'an estimated 245,000 patients with compensated MASH cirrhosis (consistent with F4c fibrosis) are currently under the care of liver specialists in the U.S.'
- Older filing section header 'Corporate Development' removed
- Older filing text 'During our first six quarters of launch in the United States, we focused our efforts on hepatologists and gastroenterologists' and endocrinologist expansion detail moved from Key Developments to market opportunity section in newer filing
- Reworded:
- Older 'metabolic dysfunction-associated fatty liver disease ("MASLD")' changed to 'metabolic dysfunction-associated steatotic liver disease ("MASLD")' in newer filing
- Older 'payors' changed to 'payers' in newer filing
- Older statement about disease awareness and growth changed from 'Over time, as disease awareness improves and disease prevalence increases, we expect the number of identified MASH patients with moderate to advanced fibrosis eligible for treatment to grow' to 'Through 2025, we estimate that the number of patients under specialist care in the U.S. has grown nearly 50% to approximately 460,000 patients with moderate to advanced fibrosis, and as disease awareness improves and disease prevalence increases, we expect the number of identified MASH patients with moderate to advanced fibrosis eligible for treatment to grow significantly going forward' in newer filing
- Notes:
- The newer filing text appears truncated at the end ('In the fourth quarter of 2026, we plan to initiate a drug-to-drug interaction study with resmetirom and consult with the FDA on the design of a P'), making complete assessment of that section impossible
- The older filing text also appears truncated ('In June 2025, we received a positive opinion...The EC granted conditional marketing authorization for Rezdiffra in August 2025 and we launched Rezdiffra in Germany in September 2025...In August 2025, we announced that the EC granted conditional marketing authorization for Rezdiffra for the treatment of MASH with moderate to advanced liver fibrosis. We launched Rezdif'), limiting assessment of Key Developments section in older filing
Risk Factors
- Added:
- Added reference to 'the European Medicines Agency' (newer filing, 2026-05-06) in forward-looking statements regarding FDA and European regulatory approval
- Added phrase 'our ability to successfully, or in a timely manner' in relation to outcomes trial results (newer filing, 2026-05-06)
- Added 'plans related to clinical trials, including anticipated timing of initiating clinical trials and the receipt of data' (newer filing, 2026-05-06)
- Added 'our ability to successfully complete business development transactions and receive the expected benefits of such transactions, and our ability to comply with our obligations under any of our current or future license agreements, including the license agreement with F. Hoffmann-La Roche AG in respect of resmetirom' (newer filing, 2026-05-06)
- Removed:
- Removed 'our ability to effectively scale our operations in Europe to successfully commercialize Rezdiffra' (older filing, 2025-11-04)
- Removed 'our expectations related to clinical trials' phrasing that included only 'anticipated timing of receipt of data' (older filing, 2025-11-04)
- Removed reference to 'the European Commission' (older filing, 2025-11-04)
- Removed 'potential sector leadership' and replaced with 'leadership position' (older filing, 2025-11-04)
- Removed standalone reference to 'our ability to comply with the covenants included in our loan facility' from separate bullet (older filing, 2025-11-04)
- Removed reference to 'Hoffman-La-Roche' agreement being related to Rezdiffra obligations (older filing, 2025-11-04)
- Reworded:
- Changed 'the European Commission' to 'the European Medicines Agency' (newer: 2026-05-06 vs older: 2025-11-04)
- Changed 'potential sector leadership' to 'leadership position' (newer: 2026-05-06 vs older: 2025-11-04)
- Changed 'our expectations related to clinical trials' to 'our expectations and plans related to clinical trials' (newer: 2026-05-06 vs older: 2025-11-04)
- Consolidated license agreement language from separate reference into integrated business development transaction statement (newer: 2026-05-06 vs older: 2025-11-04)
- Changed company name reference from 'Hoffman-La-Roche' to 'F. Hoffmann-La Roche AG' (newer: 2026-05-06 vs older: 2025-11-04)
- Changed reference from 'Annual Report on Form 10-K for the fiscal year ended December 31, 2024' to 'December 31, 2025' (newer: 2026-05-06 vs older: 2025-11-04)
- Notes:
- Balance sheet comparison shows different reporting periods (March 31, 2026 vs September 30, 2025 and December 31, 2025 vs December 31, 2024), but only forward-looking statements section was analyzed per instructions
- Page numbering differs between filings (Risk Factors on page 40 in newer vs page 38 in older), suggesting structural changes not analyzed in detail
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 11 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 11 sells ($2M) — 2 selling insiders
- Last 180 days0 buys · 37 sells ($7M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-20. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MDGL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding MDGL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 3,359,551
- Reported value $1,758,623,643
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MDGL had 1,965,849 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MDGL had 8.51% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.84 days to cover at the same settlement.
- Reported short interest (shares) 1,965,849
- Short interest (% of shares outstanding) 8.51%
- Prior settlement (shares) 2,062,862
- Reported change -4.7%
- Days to cover (reported) 4.84
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Viking Therapeutics
- Intercept Pharmaceuticals
- Galmed Pharmaceuticals (GLMD)
- 89bio (ETNB)
- Akero Therapeutics (AKRO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MDGL vs…
Frequently asked questions
What does MADRIGAL PHARMACEUTICALS, INC. (MDGL) do?
Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of liver diseases. Its primary product is Rezdiffra (resmetirom), an oral, once-daily, liver-directed thyroid hormone receptor (THR)-β agonist approved for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
What sector is MADRIGAL PHARMACEUTICALS, INC. (MDGL) in?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are MADRIGAL PHARMACEUTICALS, INC.'s (MDGL) competitors?
Notable peers of MADRIGAL PHARMACEUTICALS, INC. (MDGL) include Viking Therapeutics, Intercept Pharmaceuticals, Galmed Pharmaceuticals, 89bio and Akero Therapeutics. This peer set is informational only — not financial advice.
Is MADRIGAL PHARMACEUTICALS, INC. (MDGL) overbought or oversold right now?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MDGL come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.